Patents Assigned to Genentech
  • SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
    Publication number: 20230092354
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Application
    Filed: August 22, 2022
    Publication date: March 23, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • METHODS FOR MAKING EXTRACELLULAR VESICLES AND USES THEREOF
    Publication number: 20230090177
    Abstract: The present disclosure relates to improved methods and compositions for making extracellular vesicles (EVs). The present disclosure also relates to novel EV-based ELISA assays and kits for performing such assays, as well as methods of producing antibodies to particular antigens using EVs comprising membrane-bound antigen.
    Type: Application
    Filed: November 28, 2022
    Publication date: March 23, 2023
    Applicant: GENENTECH, INC.
    Inventors: James Thomas Koerber, Yonglian Sun
  • METHODS OF TREATING PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS USING AN INHIBITOR OF BRUTON'S TYROSINE KINASE
    Publication number: 20230091561
    Abstract: Provided herein are methods of treating Primary Progressive Multiple Sclerosis (PPMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 25, 2021
    Publication date: March 23, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Hideki GARREN, Edmond Huatung TENG, Aurelien VIACCOZ, Hans-Christian VON BUEDINGEN
  • COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER
    Publication number: 20230088701
    Abstract: Provided are combination therapies comprising a PI3K inhibitor (e.g., inavolisib), a CDK4/6 inhibitor (e.g., palbociclib), and fulvestrant; and methods of treating hormone receptor positive and HER2 negative (HR+/HER2?) locally advanced or metastatic breast cancer in a patient (preferably a patient with a PIC3CA mutant patient) comprising administering a therapeutically effective amount of inavolisib, or a pharmaceutically acceptable salt thereof, a CDK4/6 inhibitor (e.g., palbociclib), and fulvestrant or letrozole.
    Type: Application
    Filed: June 3, 2022
    Publication date: March 23, 2023
    Applicant: Genentech, Inc.
    Inventors: Jennifer O'Hara Lauchle, Michael Joseph Mamounas, Jennifer Lee Schutzman, Lori Sickels Friedman, Jian Huang
  • Bicyclic amide compounds and methods of use thereof
    Patent number: 11607396
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, R2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: March 21, 2023
    Assignee: Genentech, Inc.
    Inventors: Snahel Patel, Gregory Hamilton, Guiling Zhao, Huifen Chen
  • LACTAMS AS CBL-B INHIBITORS
    Publication number: 20230079990
    Abstract: Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same.
    Type: Application
    Filed: February 3, 2022
    Publication date: March 16, 2023
    Applicant: Genentech, Inc.
    Inventors: Jun LIANG, Araz JAKALIAN, Michael John LAMBRECHT, Robin LAROUCHE-GAUTHIER, Malcolm HUESTIS, Man Un UNG, Xiaojing WANG, Arun YADAV, Jason Robert ZBIEG, Fabio BROCCATELLI
  • TDO2 and IDO1 inhibitors
    Patent number: 11603373
    Abstract: Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: March 14, 2023
    Assignee: GENENTECH, INC.
    Inventors: Zhonghua Pei, Richard Pastor, Lewis Gazzard, Brendan Parr, Wendy Liu, Rohan Mendonca, Guosheng Wu, Po-wai Yuen
  • Apolipoprotein L1-Specific Antibodies and Methods of Use
    Publication number: 20230071609
    Abstract: This disclosure provides anti-apolipoprotein L1 (APOL1) antibodies, including anti-APOL1 antibodies that distinguish the GO and G1 forms from the G2 form of APOL1, distinguish APOL1 found on podocytes from that found on HDL particles in serum, and distinguish APOL1 from apolipoproteins L2, L3, L4 and L6 (APOL2, APOL3, APOL4 and APOL6), and methods of using the same.
    Type: Application
    Filed: June 22, 2022
    Publication date: March 9, 2023
    Applicant: Genentech Inc.
    Inventors: Suzanna Jane Scales, Nidhi Gupta, Andrew Scott Peterson
  • HARVEST OPERATIONS FOR RECOMBINANT PROTEINS
    Publication number: 20230069966
    Abstract: The present invention contemplates a method of producing a recombinant protein comprising (a) fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, and (b) harvesting said recombinant protein under conditions where dO2 levels are greater than 0%, and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable DHNA-recombinant protein adduct, as measured by an IEC assay at 310 nm.
    Type: Application
    Filed: July 13, 2022
    Publication date: March 9, 2023
    Applicant: Genentech, Inc.
    Inventors: Michael W. LAIRD, Richard ST. JOHN, Jane V. GUNSON, Kimberly KALEAS, Deepa NADARAJAH, Rachel L.E. ADAMS, Bradley R. SNEDECOR
  • PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF
    Publication number: 20230074486
    Abstract: This present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process of preparing highly concentrated antibody compositions. and highly concentrated antibody products.
    Type: Application
    Filed: November 1, 2022
    Publication date: March 9, 2023
    Applicants: Genentech, Inc., Novartis AG
    Inventor: Charles M. WINTER
  • Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
    Patent number: 11597776
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: March 7, 2023
    Assignee: Genentech, Inc.
    Inventors: Reed J Harris, Paul A. Motchnick
  • Methods of detecting polyubiquitin using anti-polyubiquitin antibodies
    Patent number: 11597761
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: March 7, 2023
    Assignee: Genentech Inc.
    Inventors: Robert F. Kelley, Vishva Dixit, Marissa L. Matsumoto
  • VISMODEGIB IN COMBINATION WITH A REPLICATION-DEFICIENT TYPE 5 ADENOVIRUS FOR EXPRESSION OF INTERFERON GAMMA FOR THE TREATMENT OF SKIN CANCER
    Publication number: 20230065168
    Abstract: Provided are methods of treating skin cancer in an individual in need thereof by administering to the individual vismodegib and a replication-deficient type 5 adenovirus for expression of interferon gamma.
    Type: Application
    Filed: March 30, 2022
    Publication date: March 2, 2023
    Applicants: ASCEND BIOPHARMACEUTICALS LTD, Genentech, Inc.
    Inventors: Clement Leong, Geoffrey Pietersz, Edward F. McKenna, JR.
  • CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE
    Publication number: 20230067037
    Abstract: The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.
    Type: Application
    Filed: April 23, 2021
    Publication date: March 2, 2023
    Applicant: Genentech, Inc.
    Inventors: Peter DRAGOVICH, Thomas PILLOW, Robert Anthony BLAKE, Ingrid WERTZ
  • USE OF HUMAN EPIDIDYMIS PROTEIN 4 (HE4) FOR ASSESSING RESPONSIVENESS OF MUC 16-POSITIVE CANCER TREATMENT
    Publication number: 20230064677
    Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
    Type: Application
    Filed: August 2, 2022
    Publication date: March 2, 2023
    Applicant: Genentech, Inc
    Inventors: Mark LACKNER, Daniel Maslyar, Yulei Wang, Walter Darbonne, Eric Humke
  • Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
    Patent number: 11591345
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: February 28, 2023
    Assignee: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
    Patent number: 11590128
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: February 28, 2023
    Assignees: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Expression of Fc-containing proteins
    Patent number: 11591382
    Abstract: The present invention provides compositions comprising a Fc-containing protein wherein substantially all the Fc domains have a C-terminal lysine. Further provided are host cell for producing said compositions, methods of making said host cells and compositions, and method of use thereof.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: February 28, 2023
    Assignee: Genentech, Inc.
    Inventors: Benjamin Haley, Zhilan Hu, John C. Joly, Amy Y. Shen, Bradley Richard Snedecor
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE
    Publication number: 20230054741
    Abstract: The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
    Type: Application
    Filed: July 22, 2021
    Publication date: February 23, 2023
    Applicant: Genentech, Inc.
    Inventors: Jason R. Zbieg, Paul Powell Beroza
  • Structures for Reducing Antibody-Lipase Binding
    Publication number: 20230048743
    Abstract: The present application relates to recombinant antibodies that are engineered to alter interactions between the antibodies and one or more endogenous lipases of a host cell used to produce the antibodies. In some cases, the antibodies are mutated in the heavy chain constant region, such as at CH1, CH2, and/or CH3. In other cases, the antibodies are mutated to alter their glycosylation profile.
    Type: Application
    Filed: July 8, 2022
    Publication date: February 16, 2023
    Applicant: Genentech Inc.
    Inventors: Elizabeth Sara Hecht, Shrenik Chetan Mehta, Wendy Noel Sandoval, Sreedhara Alavattam, Nathaniel Robert Tzizik-Swanson